CPT® Code 81450

Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis

The CPT® Code 81450 pertains to a genomic sequence analysis panel specifically designed for the evaluation of hematolymphoid neoplasms or disorders. This procedure involves the molecular genetic testing of a targeted panel of 5 to 50 genes, focusing on the interrogation for sequence variants, copy number variants, rearrangements, or isoform expression, including mRNA expression levels, if applicable. The analysis can be performed through DNA analysis alone or a combination of DNA and RNA analysis. Hematolymphoid neoplasms encompass a range of conditions, including various types of leukemia, lymphoma, and myelodysplastic syndromes. The complexity and diversity of these cancers at the molecular level necessitate advanced genetic assessments to identify specific genetic markers that can aid in the classification of cancer by its underlying biological pathways. By determining the unique genetic profile of a patient's cancer, healthcare providers can tailor targeted therapies that may lead to improved patient outcomes. The testing process typically requires the collection of blood or tissue samples, which are then analyzed using sophisticated techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) or massively parallel sequencing (MPS). These methodologies allow for a comprehensive evaluation of the genetic material, identifying critical genetic alterations that may influence treatment decisions.